Menu
GeneBe

TOE1

target of EGR1, exonuclease, the group of PARN exonuclease family

Basic information

Region (hg38): 1:45340051-45343973

Links

ENSG00000132773NCBI:114034OMIM:613931HGNC:15954Uniprot:Q96GM8AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • pontocerebellar hypoplasia type 7 (Moderate), mode of inheritance: AR
  • pontocerebellar hypoplasia type 7 (Strong), mode of inheritance: AR
  • pontocerebellar hypoplasia type 7 (Supportive), mode of inheritance: AR
  • pontocerebellar hypoplasia type 7 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Pontocerebellar hypoplasia type 7ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingCraniofacial; Endocrine; Genitourinary; Neurologic21594990; 28092684

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the TOE1 gene.

  • not provided (125 variants)
  • Familial adenomatous polyposis 2 (84 variants)
  • Hereditary cancer-predisposing syndrome (66 variants)
  • Inborn genetic diseases (28 variants)
  • not specified (24 variants)
  • Pontocerebellar hypoplasia type 7 (18 variants)
  • Carcinoma of colon (1 variants)
  • TOE1-related condition (1 variants)
  • Gastric cancer;Familial adenomatous polyposis 2 (1 variants)
  • Gastric cancer (1 variants)
  • See cases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the TOE1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
28
clinvar
3
clinvar
33
missense
2
clinvar
74
clinvar
5
clinvar
5
clinvar
86
nonsense
1
clinvar
2
clinvar
3
start loss
5
clinvar
5
frameshift
1
clinvar
2
clinvar
2
clinvar
5
inframe indel
2
clinvar
2
splice donor/acceptor (+/-2bp)
2
clinvar
2
splice region
1
3
4
non coding
1
clinvar
4
clinvar
46
clinvar
39
clinvar
3
clinvar
93
Total 3 12 131 72 11

Highest pathogenic variant AF is 0.0000263

Variants in TOE1

This is a list of pathogenic ClinVar variants found in the TOE1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
1-45340100-C-T Hereditary cancer-predisposing syndrome Uncertain significance (Jan 04, 2024)2683766
1-45340116-C-T Hereditary cancer-predisposing syndrome Likely benign (Mar 12, 2024)3236731
1-45340199-G-A not specified • Hereditary cancer-predisposing syndrome • Familial adenomatous polyposis 2 Likely benign (Oct 30, 2023)509968
1-45340199-G-C Familial adenomatous polyposis 2 • not specified • Hereditary cancer-predisposing syndrome Likely benign (Jan 29, 2024)371683
1-45340199-G-T Familial adenomatous polyposis 2 • Hereditary cancer-predisposing syndrome Conflicting classifications of pathogenicity (Jan 30, 2024)182687
1-45340201-A-G Hereditary cancer-predisposing syndrome Likely benign (Jul 16, 2017)492036
1-45340201-A-T Familial adenomatous polyposis 2 Likely benign (Sep 09, 2023)2759347
1-45340203-C-A Familial adenomatous polyposis 2 Likely benign (Oct 09, 2023)2037111
1-45340203-C-G Familial adenomatous polyposis 2 Likely benign (Nov 17, 2023)2802506
1-45340203-C-T Familial adenomatous polyposis 2 Likely benign (Apr 28, 2023)1920557
1-45340205-C-G Familial adenomatous polyposis 2 Likely benign (Oct 26, 2023)2787998
1-45340206-A-C Familial adenomatous polyposis 2 Likely benign (Mar 07, 2023)2843361
1-45340206-A-G Familial adenomatous polyposis 2 Likely benign (Sep 27, 2023)2855065
1-45340208-G-A not specified • Hereditary cancer-predisposing syndrome • Familial adenomatous polyposis 2 • Carcinoma of colon • Pontocerebellar hypoplasia type 7 Conflicting classifications of pathogenicity (Feb 01, 2024)138310
1-45340208-G-C Hereditary cancer-predisposing syndrome • Familial adenomatous polyposis 2 Likely benign (Jan 25, 2024)492035
1-45340209-T-C Familial adenomatous polyposis 2 Likely benign (May 13, 2023)414154
1-45340209-T-G Familial adenomatous polyposis 2 • Hereditary cancer-predisposing syndrome • not specified Conflicting classifications of pathogenicity (Nov 27, 2023)464715
1-45340209-TC-T Familial adenomatous polyposis 2 Likely benign (Feb 07, 2022)1649575
1-45340210-C-A Hereditary cancer-predisposing syndrome • Familial adenomatous polyposis 2 • not specified Likely benign (Dec 18, 2023)628379
1-45340210-C-G Familial adenomatous polyposis 2 Likely benign (Nov 16, 2022)2791228
1-45340210-C-T Hereditary cancer-predisposing syndrome • Familial adenomatous polyposis 2 Likely benign (Aug 30, 2022)920562
1-45340211-C-T Familial adenomatous polyposis 2 Likely benign (Nov 16, 2020)414146
1-45340212-A-C Familial adenomatous polyposis 2 Likely benign (Oct 13, 2017)533324
1-45340212-A-G Hereditary cancer-predisposing syndrome • Familial adenomatous polyposis 2 • MUTYH-related disorder Likely benign (Aug 16, 2023)492037
1-45340213-G-A Familial adenomatous polyposis 2 Uncertain significance (Nov 16, 2023)2696355

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
TOE1protein_codingprotein_codingENST00000372090 84306
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
6.04e-160.007501256690791257480.000314
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.072462980.8260.00001783349
Missense in Polyphen6588.5260.734251122
Synonymous0.1191111130.9860.000006051018
Loss of Function-0.1272322.41.030.00000133250

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0006200.000618
Ashkenazi Jewish0.000.00
East Asian0.0001090.000109
Finnish0.000.00
European (Non-Finnish)0.0003530.000343
Middle Eastern0.0001090.000109
South Asian0.0006530.000653
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Inhibits cell growth rate and cell cycle. Induces CDKN1A expression as well as TGF-beta expression. Mediates the inhibitory growth effect of EGR1. Involved in the maturation of snRNAs and snRNA 3'-tail processing (PubMed:28092684). {ECO:0000269|PubMed:12562764, ECO:0000269|PubMed:28092684}.;

Recessive Scores

pRec
0.101

Intolerance Scores

loftool
0.874
rvis_EVS
-0.27
rvis_percentile_EVS
34.71

Haploinsufficiency Scores

pHI
0.0810
hipred
Y
hipred_score
0.575
ghis
0.567

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
E
essential_gene_gene_trap
H
gene_indispensability_pred
E
gene_indispensability_score
0.853

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Toe1
Phenotype
mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);

Zebrafish Information Network

Gene name
toe1
Affected structure
post-vent region
Phenotype tag
abnormal
Phenotype quality
curved

Gene ontology

Biological process
regulation of transcription by RNA polymerase II;snRNA 3'-end processing;RNA phosphodiester bond hydrolysis, exonucleolytic
Cellular component
nucleoplasm;nucleolus;cytoplasm;Cajal body;nuclear body;nuclear speck
Molecular function
3'-5'-exoribonuclease activity;DNA-binding transcription factor activity, RNA polymerase II-specific;poly(A)-specific ribonuclease activity;protein binding;snRNA binding;metal ion binding